WO2009023331A3 - Antibodies and improved test sample handling methods for use in assays for myeloperoxidase - Google Patents

Antibodies and improved test sample handling methods for use in assays for myeloperoxidase Download PDF

Info

Publication number
WO2009023331A3
WO2009023331A3 PCT/US2008/063930 US2008063930W WO2009023331A3 WO 2009023331 A3 WO2009023331 A3 WO 2009023331A3 US 2008063930 W US2008063930 W US 2008063930W WO 2009023331 A3 WO2009023331 A3 WO 2009023331A3
Authority
WO
WIPO (PCT)
Prior art keywords
test sample
myeloperoxidase
assays
antibodies
sample handling
Prior art date
Application number
PCT/US2008/063930
Other languages
French (fr)
Other versions
WO2009023331A2 (en
Inventor
Saul A Datwyler
David J Hawksworth
Stephen C Hsu
Matthew S Matias
David P Pacenti
Mary S Pinkus
Jessie W Shih
Bryan C Tieman
Joan D Tyner
Robert N Ziemann
Original Assignee
Abbott Lab
Saul A Datwyler
David J Hawksworth
Stephen C Hsu
Matthew S Matias
David P Pacenti
Mary S Pinkus
Jessie W Shih
Bryan C Tieman
Joan D Tyner
Robert N Ziemann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/750,507 external-priority patent/US20080286818A1/en
Application filed by Abbott Lab, Saul A Datwyler, David J Hawksworth, Stephen C Hsu, Matthew S Matias, David P Pacenti, Mary S Pinkus, Jessie W Shih, Bryan C Tieman, Joan D Tyner, Robert N Ziemann filed Critical Abbott Lab
Priority to JP2010508608A priority Critical patent/JP5433570B2/en
Priority to EP08827464A priority patent/EP2158491A4/en
Priority to CA002686465A priority patent/CA2686465A1/en
Publication of WO2009023331A2 publication Critical patent/WO2009023331A2/en
Publication of WO2009023331A3 publication Critical patent/WO2009023331A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C12Q1/28—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving peroxidase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/908—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Abstract

The present disclosure relates to isolated antibodies that can be used in an assay to determine the concentration levels of myeloperoxidase (MPO) in a test sample. Additionally, the present disclosure also relates to the use of improved test sample handling methods in assays in order to preserve the original MPO levels in the test sample.
PCT/US2008/063930 2007-05-18 2008-05-16 Antibodies and improved test sample handling methods for use in assays for myeloperoxidase WO2009023331A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2010508608A JP5433570B2 (en) 2007-05-18 2008-05-16 Antibodies for use in assays for myeloperoxidase and improved test sample handling methods
EP08827464A EP2158491A4 (en) 2007-05-18 2008-05-16 Antibodies and improved test sample handling methods for use in assays for myeloperoxidase
CA002686465A CA2686465A1 (en) 2007-05-18 2008-05-16 Antibodies and improved test sample handling methods for use in assays for myeloperoxidase

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/750,507 2007-05-18
US11/750,507 US20080286818A1 (en) 2007-05-18 2007-05-18 Blood sample handling methods for improved assays for myeloperoxidase
US5006108A 2008-03-17 2008-03-17
US12/050,061 2008-03-17

Publications (2)

Publication Number Publication Date
WO2009023331A2 WO2009023331A2 (en) 2009-02-19
WO2009023331A3 true WO2009023331A3 (en) 2009-05-28

Family

ID=40351385

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/063930 WO2009023331A2 (en) 2007-05-18 2008-05-16 Antibodies and improved test sample handling methods for use in assays for myeloperoxidase

Country Status (4)

Country Link
EP (1) EP2158491A4 (en)
JP (1) JP5433570B2 (en)
CA (1) CA2686465A1 (en)
WO (1) WO2009023331A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150198589A1 (en) * 2012-06-15 2015-07-16 Ekrem Erbiz Use of edta tube with gel in elisa method
AU2018280236A1 (en) 2017-06-07 2020-01-16 Shifamed Holdings, Llc Intravascular fluid movement devices, systems, and methods of use
JP7319266B2 (en) 2017-11-13 2023-08-01 シファメド・ホールディングス・エルエルシー Intravascular fluid transfer devices, systems and methods of use
CN112004563A (en) 2018-02-01 2020-11-27 施菲姆德控股有限责任公司 Intravascular blood pump and methods of use and manufacture
EP3996797A4 (en) 2019-07-12 2023-08-02 Shifamed Holdings, LLC Intravascular blood pumps and methods of manufacture and use
US11654275B2 (en) 2019-07-22 2023-05-23 Shifamed Holdings, Llc Intravascular blood pumps with struts and methods of use and manufacture
US11724089B2 (en) 2019-09-25 2023-08-15 Shifamed Holdings, Llc Intravascular blood pump systems and methods of use and control thereof
CN111879758A (en) * 2020-07-28 2020-11-03 江苏扬新生物医药有限公司 Acridinium ester antibody labeling method and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4724213A (en) * 1985-05-24 1988-02-09 Northwestern University Murine hybridoma Lym-1 and diagnostic antibody produced thereby
US5948893A (en) * 1996-01-17 1999-09-07 The United States Of America As Represented By The Secretary Of The Navy Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody
US20020164662A1 (en) * 2001-01-02 2002-11-07 Stanley Hazen Myeloperoxidase, a risk indicator for cardiovascular disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060183174A1 (en) * 2005-02-11 2006-08-17 Leong Ng Diagnosis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4724213A (en) * 1985-05-24 1988-02-09 Northwestern University Murine hybridoma Lym-1 and diagnostic antibody produced thereby
US5948893A (en) * 1996-01-17 1999-09-07 The United States Of America As Represented By The Secretary Of The Navy Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody
US20020164662A1 (en) * 2001-01-02 2002-11-07 Stanley Hazen Myeloperoxidase, a risk indicator for cardiovascular disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2158491A4 *

Also Published As

Publication number Publication date
JP2010527592A (en) 2010-08-19
EP2158491A2 (en) 2010-03-03
JP5433570B2 (en) 2014-03-05
CA2686465A1 (en) 2009-02-19
WO2009023331A2 (en) 2009-02-19
EP2158491A4 (en) 2011-11-23

Similar Documents

Publication Publication Date Title
WO2009023331A3 (en) Antibodies and improved test sample handling methods for use in assays for myeloperoxidase
WO2010065568A3 (en) METHODS AND ASSAYS FOR MEASURING p95 AND/OR p95 IN A SAMPLE AND ANTIBODIES SPECIFIC FOR p95
WO2007035633A3 (en) Screening assays and methods
WO2006124641A3 (en) Anti-mesothelin antibodies useful for immunological assays
TW200741203A (en) Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody
HK1115192A1 (en) Methods and compositions for diagnosis and treatment of influenza
WO2009085576A3 (en) Positive control cell pellets for immunohistochemistry and methods of use thereof
WO2009134944A3 (en) Methods of determining the health status of an individual
MY172290A (en) Immunochromatography devices, methods, and, kits
SG170065A1 (en) Human embryonic stem cell methods and podxl expression
WO2009058902A3 (en) Methods and devices for analyte detection
WO2005103698A3 (en) Methods and antibodies for nitrofuran detection
WO2007114986A3 (en) Cooperative probes and methods of using them
WO2007001737A3 (en) Methods and compositions for detecting herpes simplex virus type 2
WO2009105212A3 (en) Detection of polyomavirus
WO2007024735A3 (en) Method and antibodies for detecting nitrofuran
MX2009013009A (en) High sensitivty immunoassays and kits for the determination of peptides and proteins of biological interest.
WO2015035239A3 (en) Reagents and methods for screening mps i, ii, iiia, iiib, iva, vi, and vii
MX2020006728A (en) Methods for measuring analyte and/or protein in biological samples.
ATE500503T1 (en) CD86 AND CD80 RECEPTOR COMPETITION TESTS
WO2007037910A3 (en) Specific removal of activated immune cells
GB0506183D0 (en) Antigen detection
WO2006029302A3 (en) Dioxetane-nanoparticle assemblies for energy transfer detection systems, methods of making the assemblies, and methods of using the assemblies in bioassays
GB201119585D0 (en) Assay
ATE533053T1 (en) NON-ELISPOT TEST

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08827464

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2686465

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2010508608

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008827464

Country of ref document: EP